Hair loss biotech Pelage collects $120M for Phase 3 trials
In the span of three weeks, a seven-employee biotech focused on hair loss raised $120 million for Phase 3 trials that will begin next year. Los Angeles-based Pelage Pharmaceuticals announced the Series...
View ArticleMark Pruzanski joins Alentis as CEO after leading Intercept and Versanis
Mark Pruzanski has found another fibrosis drug developer to lead, and this time he's also venturing into oncology. The biotech industry veteran has joined Swiss startup Alentis Therapeutics as its new...
View ArticleWhich big pharma had the busiest M&A team? Q3 biopharma deal analysis
Biotech execs generally point to need as the biggest driver of dealmaking. Some of the biggest players — say Merck and Bristol Myers Squibb — are losing major franchises and have a limited time to fill...
View ArticleBexorg raises $23M to test drugs on ‘rebooted’ human brains from organ donors
Drugs that look promising in animals often prove ineffective in humans. That’s especially true for diseases that afflict the brain, our most complex organ, and the one that makes us most unique from...
View ArticlePost-Hoc Live: Are the good times in biotech … back?
The other day I went online and decided, for the first time in a while, to check the price of the {$XBI}. I blinked, rubbed my eyes, and blinked again. 100??? What year is it? Quietly, gradually and...
View ArticleFormer FDA deputy Bumpus to lead Charles River's new scientific advisory board
Namandjé Bumpus, the former FDA principal deputy commissioner, will lead a new scientific advisory board at Charles River to guide its approach to non-animal based research models that can help to...
View ArticleExclusive: Lipid nanoparticle startup emerges with $31M from Khosla for in...
The red-hot race to develop simple infusions that reprogram immune cells to fight cancer and other diseases just got another entrant. Liberate Bio has raised $31 million in seed funding exclusively...
View ArticleNovo Nordisk buys kidney, blood disorder drug from Omeros
Novo Nordisk is paying up to $2.1 billion for a mid-stage blood and kidney disorder drug just weeks after saying it would focus its pipeline on obesity and diabetes under a new CEO. The Danish ...
View ArticleBoehringer makes an ADC deal with AimedBio; EyePoint’s $150M stock sale
Plus, news about Scynexis, Step Pharma, Eradivir, J&J, Omnix Medical and Mission Therapeutics: 💼 Boehringer Ingelheim does another cancer deal: The German drugmaker will pay up to $991 million to...
View ArticleLilly’s oral GLP-1 racks up two more clinical wins in diabetes
Eli Lilly’s GLP-1 pill has succeeded in two more late-stage trials in type 2 diabetes. The company said Wednesday that orforglipron beat AstraZeneca’s Farxiga at lowering patients’ blood sugar levels...
View ArticleBioNTech to get up to €95M in EU funding for a mRNA vaccine site in Africa
Two EU bodies will fund BioNTech with up to €95 million ($110 million) to help build its mRNA vaccine factory in Kigali, Rwanda, which is designed to locally supply vaccines to Africa. The Mainz,...
View ArticleEx-FDA leaders take helm of new consultancy, discuss the state of the agency
The FDA's former chief medical officer Hilary Marston left the agency in June and has already teamed up with Michael Rogers, one of the FDA's former top inspectors, to be principals of a new...
View ArticlePeter Thiel-backed Peptilogics raises $78M for prosthetic joint infection...
A Pittsburgh-based biotech supported by PayPal co-founder Peter Thiel has secured $78 million in a Series B raise that will focus on advancing its candidate for prosthetic joint infections. The cash...
View ArticleAicuris' herpes drug succeeds in Phase 3 study, company says
A privately-held German biotech said its experimental herpes drug succeeded in a Phase 3 study, setting up plans to apply for US approval in 2026. Patients on Aicuris' drug, called pritelivir,...
View ArticleAdcytherix raises €104M Series A to back new ADC drug
A French team of researchers and biopharma executives is taking the wraps off a large Series A round that will help get its lead antibody-drug conjugate program into its first human trials. Adcytherix...
View ArticleChicago biotech EVOQ pens $500M autoimmune pact with Sanofi
A small Chicago biotech looking to treat autoimmune diseases by activating regulatory T cells (Tregs) — an area that is fresh off a Nobel Prize win — has signed up Sanofi as its third ...
View ArticleConnecticut biotech Veradermics gets $150M for Phase 3 trials of oral Rogaine
Veradermics has raised the week's second megaround for a hair loss biotech, collecting a $150 million Series C from prominent life sciences investors. The New Haven, CT-based biotech plans to use the...
View ArticleJ&J says Darzalex, Tecvayli combo improves survival odds in multiple myeloma
Johnson & Johnson announced Thursday that a combination of two multiple myeloma drugs — a Darzalex injection and the T cell engager Tecvayli — not only kept cancer at bay for longer, but also...
View ArticleNovartis’ Fabhalta gets confirmatory late-stage trial win in kidney disease IgAN
Novartis expects Fabhalta’s accelerated approval in the kidney disease known as IgA nephropathy to be converted into a full approval after the drug met its primary endpoint in a confirmatory Phase 3...
View ArticleTown Hall Ventures raises $440M healthcare technology fund
Town Hall Ventures, an eight-year-old venture firm investing in healthcare startups focused on underserved communities, on Wednesday announced a $440 million fourth fund. The money will be used to help...
View Article